Harvard Pilgrim Health Care agrees to cover PCSK9 inhibitor

 - Payout
Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Harvard Pilgrim Health Care agreed to cover evolocumab (Repatha, Amgen) at a discount in the first "pay-for-performance" contract for the proprotein convertase subtilisin/kexin type 9 inhibitor, the Boston Globe reports. In August, the FDA approved evolocumab, which is an injectable medication that lowers high-density lipoprotein cholesterol.

For more, check out the link below: